HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.

Publikation

HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.

Wissenschaftlicher Artikel/Review - 05.07.2024

Besse Andrej, Sedlarikova Lenka, Büchler Lorina, Kraus Marianne, Yang Chieh-Hsiang, Strakova Nicol, Soucek Karel, Navratil Jiri, Svoboda Marek, Welm Alana L, Jörger Markus, Driessen Christoph, Besse Lenka

Zitation

Besse A, Sedlarikova L, Büchler L, Kraus M, Yang C, Strakova N, Soucek K, Navratil J, Svoboda M, Welm A, Jörger M, Driessen C, Besse L. HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer. Br J Cancer 2024

Projekt

In vitro proteotoxic synergism of nelfinavir and carfilzomib in solid cancer cell lines

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Br J Cancer 2024

Veröffentlichungsdatum

05.07.2024

eISSN (Online)

1532-1827

Kurzbeschreibung/Zielsetzung

Resistance to chemotherapy is a major problem in the treatment of patients with triple-negative breast cancer (TNBC). Preclinical data suggest that TNBC is dependent on proteasomes; however, clinical observations indicate that the efficacy of proteasome inhibitors in TNBC may be limited, suggesting the need for combination therapies.